Introduction {#s1}
============

Males and females have distinct biological, immunological, and endocrine differences that result in different disease processes and outcomes. Sex-specific differential gene expression and molecular-level variation have been reported to influence blood pressure, cardiovascular health, and kidney function ([@B1]--[@B6]). Females, in general, have a heightened capability to activate a more robust immune response, offering protection against many infectious disease processes, but may predispose them to an array of autoimmune diseases ([@B7]--[@B12]). Males and females also express immunological dimorphisms. Females have two X chromosomes in comparison to the XY in males. The random transcriptional inactivation of X chromosomes in females may also help offset certain mutation-related dysregulation of the immune system ([@B13]). Differences in endocrine system regulation in females compared to males significantly affect disease processes including respiratory, cardiovascular, and renal disease ([@B6], [@B14]--[@B18]). As nations across the world navigate their way through the Coronavirus disease 2019 (COVID-19) pandemic, clinical, research, and public health experts have observed that this disease does not affect all individuals alike.

Since the beginning of 2020, the world\'s healthcare professionals have tirelessly attempted to mitigate the impact of the COVID-19 pandemic. With over 6.5 million confirmed cases and 387,000 deaths worldwide as of June 5th, 2020, a post-COVID-19 pandemic era is not within the near foreseeable future ([@B19]). The United States, one of the epicenters for the disease, has documented over 1.8 million confirmed cases and 108,000 deaths related to COVID-19 ([@B19], [@B20]). Many recent studies have highlighted certain risk factors that cause specific populations to be disproportionately susceptible to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Currently known risk factors for severe clinical outcomes of COVID-19 include: advanced age (65 years and older), chronic lung diseases, immunocompromised status, and other comorbidities such as hypertension, diabetes, or cardiovascular disease ([@B21]--[@B25]).

Observations in COVID-19 patient data involving clinical characteristics highlight specific disparities in males and females. A recent case-series study looking at COVID-19 and SARS patients showed that while males and females had the similar disease prevalence, males with COVID-19 were at higher risk for worse clinical outcomes and death ([@B26]). In this study, as the patient age and the documented comorbidities (i.e., cardiovascular diseases, diabetes, chronic lung diseases, or hypertension) increased, the risk of severity and mortality in both COVID-19 and SARS patients increased. However, the mortality rate in males was 2.4 times that of their age-matched female counterparts (70.3 and 29.7%, respectively).

Furthermore, a nationwide COVID-19 surveillance study conducted in Italy indicated that male mortality rates related to COVID-19 were disproportionately higher than that of female patients with a ratio as much as 4 to 1 ([@B23]). Other systematic reviews performed to characterize clinical features or risk factors for COVID-19, have also identified the sex-specific disparities in disease severity and mortality ([@B25], [@B27]). However, the clinical importance of male sex as a risk factor for COVID-19 has mainly been overlooked or explained as a potential confounder to other environmental factors such as smoking or tobacco product usage ([@B28]). While various studies have made observations of the sex-specific disparities of COVID-19, this specific relationship has not been adequately established. The sex-specific disease severity is an important clinical consideration as it affects all patient populations. Recognition of male sex as a risk factor for COVID-19 will impact both preventative measures and clinical patient management protocols.

The goal of this systematic review and meta-analysis is to identify whether males are more susceptible to COVID-19, severe forms of the disease, or mortality related to COVID-19. To address this question, we systematically reviewed the literature using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We performed a meta-analysis of the selected study populations comparing male and female COVID-19 patients. This review incorporated three online databases and research studies published between December 15th, 2019, and April 16th, 2020. We characterized the influence of sex as a risk factor for COVID-19 measuring the following clinical outcomes: all lab-confirmed cases, severe cases, critically ill cases, and mortality.

Methods {#s2}
=======

Literature Search and Research Study Selection
----------------------------------------------

We performed a comprehensive systematic literature search of three online databases, PubMed (LitCOVID), Embase (OVID), and Web of Science (WoS), from December 15th, 2019, to April 16th, 2020. We identified all research articles related to COVID-19 that contained any sex-specific patient or clinical characterizations. The search terms and keywords used to identify research studies for the meta-analysis were: COVID-19, male, female, men, women, sex, and gender ([Supplemental Table 1](#SM2){ref-type="supplementary-material"}). We reviewed references of review, perspectives, systematic reviews, and meta-analysis articles of the include articles to ensure comprehensiveness of our search. All our search results were evaluated using the PRISMA statement. We reviewed the abstracts and tables of each of the articles to identify the presence of sex-specific (male and female) COVID-19 case numbers. Studies that did not contain an abstract in English were excluded from our study during the screening stage.

Eligibility Criteria
--------------------

The inclusion criteria for research article selection was as stated below. Study population: patients with lab-confirmed COVID-19 diagnosis. Study design: case series or cross-sectional study that did not exclude any lab-confirmed COVID-19 patients. Outcomes measure: at least one outcome reported with male to female ratio among lab-confirmed clinical cases, severe cases, critical cases, and mortality. Research study: only peer-reviewed research publications were included. Commentary articles, perspectives, review articles, and surveillance reports were excluded. The following case definitions were used in this study. All cases were lab-confirmed COVID-19 patients. Severe cases were defined as having at least one of the following clinical findings: (a) breathing rate ≥30/min, (b) oxygen saturation (SpO~2~) ≤ 93% at rest, or (c) ratio of the partial pressure of arterial oxygen (PaO~2~) to the fraction of inspired oxygen (FiO~2~) ≤300 mmHg. The severe case definition followed the American Thoracic Society guidelines for community-acquired pneumonia ([@B29]). Critical cases were defined as: (a) received mechanical ventilation; (b) clinically diagnosed with shock symptoms, (c) received care in the intensive care unit (ICU) or (d) transfer to a tertiary care hospital.

Data Extraction and Quality Assessment
--------------------------------------

All articles identified through the keyword search from the online databases were organized into an Excel® spreadsheet. Following the removal of duplicates, articles were subjected to evaluation, and five investigators did data extraction. Research studies were screened using the abstract and any tabulated clinical characteristics of COVID-19 patients. Directly after that, research articles were again screened to identify any discrepancies by an independent investigator. The screened articles were assessed against the study selection criteria by two independent investigators, and any differences in selected articles were revisited, and a definitive determination was made. We organized studies according to the study period, study location, and patient population included in the analysis to ensure we were not using the same COVID-19 cases more than once in our analysis.

Selected Study Bias Risk Assessment
-----------------------------------

A bias risk assessment was conducted on studies included in the meta-analysis utilizing the methodological index for non-randomized studies (Minors) criteria at the study level ([@B30]). Each of the selected articles was scored with 0 (not reported), 1 (reported but inadequate), or 2 (reported and adequate). The highest score possible was 16 for non-comparative studies according to Minors guidelines.

Statistical Analysis of Selected Data Sets
------------------------------------------

Statistical analysis was conducted using *R* ([@B31]) with the meta-analysis packages *meta* ([@B32]) and *dmetar* ([@B33]) ([Supplemental Data 1](#SM1){ref-type="supplementary-material"}). The principal summary measures of the meta-analysis were proportions of males in four different COVID-19 categories. The four groups were: (a) all confirmed COVID-19 cases, (b) severe cases of COVID-19 as defined in section Data Extraction and Quality Assessment, (c) critically ill cases of COVID-19 as defined in section Data Extraction and Quality Assessment, and (d) deaths associated with COVID-19. Agresti-Coull confidence intervals were used for individual studies. Studies were combined using the inverse variance method on the raw proportions with the DerSimonian-Laird estimator for the between-groups variance estimator (τ^2^) and the Jackson method for combined confidence intervals. Transformations of raw proportions were calculated for the combined estimates (*log, logit, arcsin*, and *Freeman-Tukey double arcsin*), but the results were so similar they are not shown. The proportion of variation in treatment effects was estimated with *I*^2^. To assess bias across studies, funnel plots were constructed for each of the four different categories, and Egger\'s bias test conducted. To determine if there were region-specific differences among populations in Asian and Western countries, we sub-divided the COVID-19 critically ill patient populations into these two regions and analyzed them.

Clinical Outcomes Median Age Calculation
----------------------------------------

To combine the ages, in 20 of the articles, the median age of patients was given, along with sometimes interquartile range, sometimes min and max. In 10 of the articles, mean and standard deviation (SD) were presented. In one article ([@B34]), the mean age was given without SD. We used linear regression on the other 10 (mean, SD) pairs to estimate the SD to be 14.5 years. To combine the ages, we chose to convert means to medians because there would be fewer unknown statistics to estimate, and typical disease distributions are skewed. To convert, we fit a negative binomial distribution to the mean and SD using the method of moments. With the complete list of medians, we used *R*\'s *metamedian* ([@B35]) package to obtain summarized confidence intervals for each of the four categories.

Results {#s3}
=======

Research Study Selection and Quality Assessment
-----------------------------------------------

We identified 786 research articles that matched our search terms. After the duplicated were removed, 414 unique research articles were screened. Following the screening process, 353 articles with incomplete data were excluded. We then identified 61 research articles with sex-specific case numbers and reviewed full-length articles to assess their eligibility for our study according to the selection criteria. Thirty articles did not fit the selection criteria and were excluded from the meta-analysis. Reasons for exclusion were: not a primary research study (a surveillance report or perspective), did not include consecutive patients or did not meet with the case or severity definitions. The 31 research articles eligible for this meta-analysis were used for qualitative synthesis and quantitative analysis ([Figure 1](#F1){ref-type="fig"}). The 31 eligible articles were subjected to a bias assessment using the Minors criteria at the study level ([@B30]). All 31 selected articles scored between 12 and 14 points, with 16 being the highest for non-randomized controlled studies ([Table 1](#T1){ref-type="table"}). The relatively high scores indicated that we were likely not introducing any significant systematic biases.

![COVID-19 sex-specific clinical outcomes flow diagram of the inclusion criteria of studies eligible for meta-analysis. Flow diagram template adopted from the PRISMA approach to meta-analysis ([@B36]).](fmed-07-00348-g0001){#F1}

###### 

Bias risk assessment on the studies included in the meta-analysis using the methodological index for non-randomized studies (Minors) criteria ([@B30]).

  **References**   **Study population**   **(1)**   **(2)**   **(3)**   **(4)**   **(5)**   **(6)**   **(7)**   **(8)**   **Score**
  ---------------- ---------------------- --------- --------- --------- --------- --------- --------- --------- --------- -----------
  ([@B37])         48                     2         2         2         2         2         2         2         0         14
  ([@B38])         24                     2         2         2         2         2         1         1         0         12
  ([@B39])         102                    2         2         2         2         2         1         1         0         12
  ([@B40])         249                    2         2         2         2         2         1         1         0         12
  ([@B41])         99                     2         2         2         2         2         2         2         0         14
  ([@B42])         203                    2         2         2         2         2         2         2         0         14
  ([@B43])         113                    2         2         2         2         2         1         2         0         13
  ([@B44])         54                     2         2         2         2         2         1         1         0         12
  ([@B45])         179                    2         2         2         2         2         2         1         0         13
  ([@B46])         109                    2         2         2         2         2         2         2         0         14
  ([@B47])         85                     2         2         2         2         2         2         2         0         14
  ([@B34])         68                     2         2         2         2         2         2         2         0         14
  ([@B22])         1591                   2         2         2         2         2         2         2         0         14
  ([@B48])         1,096                  2         2         2         2         2         1         1         0         12
  ([@B49])         41                     2         2         2         2         2         1         1         0         12
  ([@B50])         54                     2         2         2         2         2         2         2         0         14
  ([@B51])         548                    2         2         2         2         2         1         2         0         13
  ([@B52])         137                    2         2         2         2         2         2         2         0         14
  ([@B53])         214                    2         2         2         2         2         1         1         0         12
  ([@B54])         452                    2         2         2         2         2         1         1         0         12
  ([@B55])         85                     2         2         2         2         2         1         1         0         12
  ([@B56])         135                    2         2         2         2         2         1         1         0         12
  ([@B57])         138                    2         2         2         2         2         1         1         0         12
  ([@B58])         125                    2         2         2         2         2         2         2         0         12
  ([@B59])         1,012                  2         2         2         2         2         1         2         0         13
  ([@B60])         80                     2         2         2         2         2         2         2         0         14
  ([@B61])         79                     2         2         2         2         2         1         1         0         12
  ([@B62])         90                     2         2         2         2         2         2         2         0         14
  ([@B63])         149                    2         2         2         2         2         2         2         0         14
  ([@B64])         18                     2         2         2         2         2         2         2         0         14
  ([@B65])         140                    2         2         2         2         2         1         1         0         12

*(1) A clearly stated aim; (2) Inclusion of consecutive patients; (3) Prospective collection of data; (4) Endpoints appropriate to the aim of the study; (5) Unbiased assessment of the study endpoint; (6) Follow-up period appropriate to the aim of the study; (7) Loss to follow-up less than 5%; (8) Prospective calculation of the study size. The items are scored 0 (not reported), 1 (reported but inadequate), or 2 (reported and adequate). The global ideal score being 16 for non-comparative studies*.

Study Population Demographics
-----------------------------

Within our selected studies, 7,556 lab-confirmed COVID-19 cases were identified. Of these 31 studies, 24 were from various cities in China and included a sample of 5,629 lab-confirmed cases. Two studies were from South Korea and Singapore, which included a sample of 72 lab-confirmed cases. The other five studies were from Europe and North America, having a sample of 1,855 lab-confirmed cases ([Figure 2](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). Most of the early studies came from China with study periods from December 11th, 2019, to February 24th, 2020. Most of the later studies came from other countries with study periods from January 23rd to April 5th, 2020 ([Figure 3](#F3){ref-type="fig"}). These patterns reflect the movement of epicenters for COVID-19 from the East to the West.

![Countries and locations for the selected studies used in the meta-analysis. Total patient populations in each of the study locations are illustrated with a colored circle and correspond to the size of study populations. Each point represents a research study, except for China, which represents the total patient population from 24 different studies. The world map was obtained from Wikimedia Commons, the free media repository licensed under the Creative Commons Attribution-Share Alike 3.0 Unported license.](fmed-07-00348-g0002){#F2}

###### 

Demographics of all studies included in the meta-analysis with sex-specific disease severity.

  **References**   **Country (City or province)**   **Study population**   **Age[^a^](#TN1){ref-type="table-fn"} (*mean* or median)**   **All cases[^b^](#TN2){ref-type="table-fn"} (male %)**   **Severe cases[^c^](#TN3){ref-type="table-fn"} (male %)**   **Critical cases[^d^](#TN4){ref-type="table-fn"} (male %)**   **Mortality (male %)**
  ---------------- -------------------------------- ---------------------- ------------------------------------------------------------ -------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------- ------------------------
  ([@B37])         Spain (Vitoria)                  48                     *63.2*                                                       --                                                       --                                                          56.3                                                          --
  ([@B38])         United States (Seattle)          24                     *64.0*                                                       --                                                       --                                                          62.5                                                          --
  ([@B39])         China (Wuhan)                    102                    54.0                                                         52.0                                                     --                                                          --                                                            76.5
  ([@B40])         China (Shanghai)                 249                    51.0                                                         50.6                                                     --                                                          86.4                                                          --
  ([@B41])         China (Wuhan)                    99                     *55.5*                                                       67.7                                                     --                                                          --                                                            --
  ([@B42])         China (Wuhan)                    203                    54.0                                                         53.2                                                     --                                                          --                                                            --
  ([@B43])         China (Wuhan)                    113                    68.0                                                         --                                                       --                                                          --                                                            73.5
  ([@B44])         China (Wuhan)                    54                     39.0                                                         66.7                                                     69.8                                                        --                                                            --
  ([@B45])         China (Wuhan)                    179                    *57.6*                                                       54.2                                                     --                                                          --                                                            47.6
  ([@B46])         China (Wuhan)                    109                    *70.7*                                                       --                                                       --                                                          --                                                            67.9
  ([@B47])         China (Wuhan)                    85                     *65.8*                                                       --                                                       --                                                          --                                                            72.9
  ([@B34])         United Kingdom                   68                     *42.5*                                                       47.1                                                     --                                                          --                                                            --
  ([@B22])         Italy (Milan)                    1,591                  63.0                                                         --                                                       --                                                          82.0                                                          --
  ([@B48])         China                            1,096                  47.0                                                         58.1                                                     57.8                                                        67.2                                                          --
  ([@B49])         China (Wuhan)                    41                     49.0                                                         73.2                                                     --                                                          84.6                                                          --
  ([@B50])         South Korea                      54                     75.5                                                         --                                                       --                                                          --                                                            61.1
  ([@B51])         China (Wuhan)                    548                    60.0                                                         50.9                                                     56.9                                                        --                                                            --
  ([@B52])         China (Wuhan)                    137                    57.0                                                         44.5                                                     --                                                          --                                                            --
  ([@B53])         China (Wuhan)                    214                    *52.7*                                                       40.7                                                     50.0                                                        --                                                            --
  ([@B54])         China (Wuhan)                    452                    58.0                                                         52.0                                                     54.2                                                        --                                                            --
  ([@B55])         France (Lille)                   124                    60                                                           --                                                       --                                                          72.6                                                          --
  ([@B56])         China (Chongqing)                135                    47.0                                                         53.3                                                     52.5                                                        --                                                            --
  ([@B57])         China (Wuhan)                    138                    56.0                                                         54.3                                                     --                                                          61.1                                                          --
  ([@B58])         China (Fuyang)                   125                    *38.8*                                                       56.8                                                     --                                                          --                                                            --
  ([@B59])         China (Wuhan)                    1,012                  50.0                                                         51.8                                                     --                                                          62.0                                                          --
  ([@B60])         China (Jiangsu)                  80                     *46.1*                                                       48.8                                                     --                                                          --                                                            --
  ([@B61])         China (Wuhan)                    79                     60.0                                                         55.7                                                     64.3                                                        --                                                            --
  ([@B62])         China (Wuhan)                    90                     50.0                                                         43.3                                                     --                                                          --                                                            --
  ([@B63])         China (Wenzhou)                  149                    *45.1*                                                       54.4                                                     --                                                          --                                                            --
  ([@B64])         Singapore                        18                     47.0                                                         50.0                                                     --                                                          --                                                            --
  ([@B65])         China (Wuhan)                    140                    57.0                                                         50.7                                                     56.9                                                        --                                                            --

*The mean or median age of the study population for each research study. In the event a study had a severity or mortality sub-population, age is listed for only the total study population. Mean ages are indicated in italics*.

*All consecutive patients with lab-confirmed cases of COVID-19 within the study period*.

*Severe case defined as having at least one of the following clinical findings: (a) breathing rate ≥30/min, (b) pulse oximeter oxygen saturation (SpO~2~) ≤93% at rest, or (c) ration of the partial pressure of arterial oxygen (PaO~2~) to the fraction of inspired oxygen (FiO~2~) ≤300 mmHg*.

*Critical case defined as (a) received mechanical ventilation; (b) clinically diagnosed with shock, (c) received care in the intensive care unit (ICU) or (d) transferred to a tertiary care hospital*.

![Timeline illustrating the study period of each of the research studies used for the meta-analysis. Each research study used for the meta-analysis is represented by the study name (study sample), duration of the study with a line corresponding to the length of the study, and the start and end date of the study. The studies were ordered according to the start date of each study.](fmed-07-00348-g0003){#F3}

Meta-Analysis and Bias Assessment
---------------------------------

The principal quantitative results are contained in the forest plots shown on the left side of [Figures 4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}. The individual confidence intervals are shown, by study, with the combined proportion for each group and confidence interval at the bottom. A random-effects model was used for the combined proportion to check for heterogeneity (τ^2^= between-group variation and *I*^2^= proportion of total variation in the estimates of treatment effects due to heterogeneity). We used the following guidelines for interpreting *I*^2^: *I*^2^ = 25% is small heterogeneity; *I*^2^ = 50% is medium heterogeneity; and *I*^2^ = 75% is large heterogeneity ([@B66]). The heterogeneity statistics (τ^2^ and *I*^2^) are shown at the bottom left of the forest plots.

![The proportion of males in all lab-confirmed COVID-19 cases. **(A)** Forest plot of sex-distribution in all lab-confirmed COVID-19 cases in each of the studies. Proportions of males and the 95% confidence intervals (CIs) are indicated. The vertical dotted line represents the combined proportion of all studies. The diamond represents the combined 95% CI, the left and right endpoints of which are the lower and upper bounds of the CI, respectively. **(B)** Funnel plot with 95% confidence region of sex-distribution in all lab-confirmed COVID-19 cases in each of the studies.](fmed-07-00348-g0004){#F4}

![The proportion of males in COVID-19 severe cases, critical cases, and mortalities. **(A,C,E)** Forest plot of sex-distribution in COVID-19 cases in each of the studies. Proportions of males and the 95% confidence intervals (CIs) are indicated. The vertical dotted lines represent the combined proportion of all studies. The diamond represents the combined 95% CI, the left and right endpoints of which are the lower and upper bounds of the CI, respectively. **(A)** Severe cases defined as having at least one of the following clinical findings: breathing rate ≥30/min, pulse oximeter oxygen saturation (SpO2) ≤93% at rest, or ration of the partial pressure of arterial oxygen (PaO~2~) to the fraction of inspired oxygen (FiO~2~) ≤300 mmHg. **(C)** Critical case defined as: received mechanical ventilation, clinically diagnosed with shock, received care in the intensive care unit (ICU), or transferred to a tertiary care hospital. **(E)** Mortality defined as all deaths in COVID-19 patients that occurred during the study period. **(B,D,F)** Funnel plot with 95% confidence region of sex-distribution in COVID-19 severe cases, critical cases, and mortality in each of the studies.](fmed-07-00348-g0005){#F5}

Sex-Specific COVID-19 Case Distribution
---------------------------------------

A total of 23 studies with 5,408 lab-confirmed COVID-19 cases were analyzed ([Table 3](#T3){ref-type="table"}). Our results from the randomized effects model meta-analysis showed that in the sex-distribution of all COVID-19 cases, males accounted for 53% (95% CI \[0.51, 0.55\]) ([Figure 4A](#F4){ref-type="fig"}). Female patients made up 47% of all COVID-19 cases. There is medium heterogeneity between the set of overall population proportions (*I*^2^ = 64%, τ = 0.05). A funnel plot was drawn to assess the publication bias ([Figure 4B](#F4){ref-type="fig"}). The publication bias test results: Egger\'s test (*p* = 0.88) indicated that there was no publication bias.

###### 

All confirmed cases of COVID-19 included in the meta-analysis.

  **References**   **Age[^a^](#TN5){ref-type="table-fn"} (*mean* or median)**   **Total number of cases[^b^](#TN6){ref-type="table-fn"}**   **Number of male cases**   **Number of female cases**   **All cases (male %)**
  ---------------- ------------------------------------------------------------ ----------------------------------------------------------- -------------------------- ---------------------------- ------------------------
  ([@B39])         54.0                                                         102                                                         53                         49                           52.0
  ([@B40])         51.0                                                         249                                                         126                        123                          50.6
  ([@B41])         *55.5*                                                       99                                                          67                         32                           67.7
  ([@B42])         54.0                                                         203                                                         108                        95                           53.2
  ([@B44])         39.0                                                         54                                                          36                         18                           66.7
  ([@B45])         *57.6*                                                       179                                                         97                         82                           54.2
  ([@B34])         *42.4*                                                       68                                                          32                         36                           47.1
  ([@B48])         47.0                                                         1,096                                                       637                        459                          58.1
  ([@B49])         49.0                                                         41                                                          30                         11                           73.2
  ([@B51])         60.0                                                         548                                                         279                        269                          50.9
  ([@B52])         57.0                                                         137                                                         61                         76                           44.5
  ([@B53])         *52.7*                                                       214                                                         87                         127                          40.7
  ([@B54])         58.0                                                         452                                                         235                        217                          52.0
  ([@B56])         47.0                                                         135                                                         72                         63                           53.3
  ([@B57])         56.0                                                         138                                                         75                         63                           54.3
  ([@B58])         *38.8*                                                       125                                                         71                         54                           56.8
  ([@B59])         50.0                                                         1,012                                                       524                        488                          51.8
  ([@B60])         *46.1*                                                       80                                                          39                         41                           48.8
  ([@B61])         60.0                                                         79                                                          44                         35                           55.7
  ([@B62])         50.0                                                         90                                                          39                         51                           43.3
  ([@B63])         *45.1*                                                       149                                                         81                         68                           54.4
  ([@B64])         47.0                                                         18                                                          9                          9                            50.0
  ([@B65])         57.0                                                         140                                                         71                         69                           50.7

*The mean or median age of the study population reported by each research study. Mean ages are indicated in italics*.

*All consecutive patients with lab-confirmed cases of COVID-19 within the study period*.

Sex-Specific COVID-19 Severe Case Distribution
----------------------------------------------

A total of 8 studies with 985 severe COVID-19 cases were analyzed ([Table 4](#T4){ref-type="table"}). Our results from the randomized effects model meta-analysis showed that in the sex-distribution of all COVID-19 severe cases, males accounted for 56% (95% CI \[0.53, 0.59\]) ([Figure 5A](#F5){ref-type="fig"}). Female patients made up 44% of all COVID-19 severe cases. There is no heterogeneity for the severe population proportions (*I*^2^ = 0%, τ = 0. 0). A funnel plot was drawn to assess the publication bias ([Figure 5B](#F5){ref-type="fig"}). The publication bias test results: Egger\'s test (*p* = 0.40) indicated that there was no publication bias.

###### 

All severe cases of COVID-19 included in the meta-analysis.

  **References**   **Age[^a^](#TN7){ref-type="table-fn"} (*mean* or median)**   **Total no. of severe cases[^b^](#TN8){ref-type="table-fn"}**   **No. of male severe cases**   **No. of female severe cases**   **Severe cases (male %)**
  ---------------- ------------------------------------------------------------ --------------------------------------------------------------- ------------------------------ -------------------------------- ---------------------------
  ([@B44])         38.0                                                         43                                                              30                             13                               69.8
  ([@B48])         52.0                                                         173                                                             100                            73                               57.8
  ([@B51])         65.0                                                         269                                                             153                            116                              56.9
  ([@B53])         *58.2*                                                       88                                                              44                             44                               50.0
  ([@B54])         61.0                                                         286                                                             155                            131                              54.2
  ([@B56])         56.0                                                         40                                                              21                             19                               52.5
  ([@B61])         62.5                                                         28                                                              18                             10                               64.3
  ([@B65])         64.0                                                         58                                                              33                             25                               56.9

*The mean or median age of the study population reported by each research study. Mean ages are indicated in italics*.

*Severe case defined as having at least one of the following clinical findings: (a) breathing rate ≥30/min, (b) pulse oximeter oxygen saturation (SpO~2~) ≤93% at rest, or (c) ration of the partial pressure of arterial oxygen (PaO~2~) to the fraction of inspired oxygen (FiO~2~) ≤300 mmHg*.

Sex-Specific COVID-19 Critically Ill Case Distribution
------------------------------------------------------

A total of 9 studies with a total of 2,025 critical COVID-19 cases were analyzed ([Table 5](#T5){ref-type="table"}). Our results from the randomized effects model meta-analysis showed that in the sex-distribution of all COVID-19 critically ill cases, males accounted for 71% (95% CI \[0.63, 0.79\]) ([Figure 5C](#F5){ref-type="fig"}). Female patients made up 29% of all COVID-19 critical cases. There was large heterogeneity between the critical population proportions (*I*^2^ = 83%, τ = 0.10). A funnel plot was drawn to assess the publication bias ([Figure 5D](#F5){ref-type="fig"}). The publication bias test results: Egger\'s test (*p* = 0.02) indicated that there could be some publication bias introduced by the Grasselli et al. ([@B22]) study.

###### 

All critical cases of COVID-19 included in the meta-analysis.

  **References**   **Age[^a^](#TN9){ref-type="table-fn"} (*mean* or median)**   **Total no. of critical cases[^b^](#TN10){ref-type="table-fn"}**   **No. of male critical cases**   **No. of female critical cases**   **Critical cases (male %)**
  ---------------- ------------------------------------------------------------ ------------------------------------------------------------------ -------------------------------- ---------------------------------- -----------------------------
  ([@B37])         *63.2*                                                       48                                                                 27                               21                                 56.3
  ([@B38])         *64.0*                                                       24                                                                 15                               9                                  62.5
  ([@B40])         51.0                                                         22                                                                 19                               3                                  86.4
  ([@B22])         63.0                                                         1,591                                                              1,304                            287                                82.0
  ([@B48])         63.0                                                         67                                                                 45                               22                                 67.2
  ([@B49])         49.0                                                         13                                                                 11                               2                                  84.6
  ([@B55])         60                                                           124                                                                90                               34                                 75.3
  ([@B57])         66.0                                                         36                                                                 22                               14                                 61.1
  ([@B59])         55.5                                                         100                                                                62                               38                                 62.0

*The mean or median age of the study population reported by each research study. Mean ages are indicated in italics*.

*Critical cases defined as (a) received mechanical ventilation; (b) clinically diagnosed with shock, (c) received care in the intensive care unit (ICU) or (d) transferred to a tertiary care hospital*.

Sex-Specific COVID-19 Mortality Distribution
--------------------------------------------

A total of 6 studies with a total of 399 mortalities related to COVID-19 cases were analyzed ([Table 6](#T6){ref-type="table"}). Our results from the randomized effects model meta-analysis showed that in the sex-distribution of all COVID-19 mortalities, males accounted for 69% (95% CI \[0.63, 0.75\]) ([Figure 5E](#F5){ref-type="fig"}). Female patients made up 31% of all COVID-19 mortalities. The heterogeneity for the mortality population proportions is small (*I*^2^ = 34%, τ = 0.04). A funnel plot was drawn to assess the publication bias ([Figure 5F](#F5){ref-type="fig"}). The publication bias test results: Egger\'s test (*p* = 0.26) indicated that there was no observable publication bias.

###### 

All deaths in COVID-19 patients included in the meta-analysis.

  **References**   **Age[^a^](#TN11){ref-type="table-fn"} (*mean* or median)**   **Total number of deaths[^b^](#TN12){ref-type="table-fn"}**   **Number of male deaths**   **Number of female deaths**   **Mortality (male %)**
  ---------------- ------------------------------------------------------------- ------------------------------------------------------------- --------------------------- ----------------------------- ------------------------
  ([@B39])         72.0                                                          17                                                            13                          4                             76.5
  ([@B43])         68.0                                                          113                                                           83                          30                            73.5
  ([@B45])         *70.2*                                                        21                                                            10                          11                            47.6
  ([@B46])         *70.7*                                                        109                                                           74                          35                            67.9
  ([@B47])         *65.8*                                                        85                                                            62                          23                            72.9
  ([@B50])         75.5                                                          54                                                            33                          21                            61.1

*The mean or median age of the study population reported by each research study. Mean ages are indicated in italics*.

*All consecutive number of deaths in COVID-19 patients that occurred during the study period*.

Sex-Specific COVID-19 Distribution in Asia and the West
-------------------------------------------------------

Sex-specific differences in clinical outcomes of COVID-19 cases in China were thought to be related to cultural and social differences in males and females ([@B28]). We investigated if our study results hold in different regions of the world. COVID-19 critically ill patient data sets were divided into two groups: Asia and West, and subgroup analyses were performed. We selected the critically ill patient group for Asia and the West as it was the only disease category that included multiple studies from both Asia and West for an appropriate comparison and statistical analysis.

A total of 5 studies from Asia, with a total of 238 critical COVID-19 cases were analyzed. Our results from the randomized effects model meta-analysis showed that in the sex-distribution of COVID-19 critically ill cases from Asia, males accounted for 71% (95% CI \[0.61, 0.81\]) ([Figure 6A](#F6){ref-type="fig"}). Female patients made up 29% of all COVID-19 critical cases in Asia. There was medium heterogeneity between the critical population proportions (*I*^2^ = 64%, τ = 0.0082). A funnel plot was drawn to assess the publication bias in studies from Asia ([Figure 6B](#F6){ref-type="fig"}). The publication bias test results: Egger\'s test (*p* = 0.26) indicated that there was no observable publication bias.

![Comparison of the proportion of males in COVID-19 critical cases in Asia and the West. **(A,C)** Forest plot of sex-distribution in COVID-19 critical cases in each of the studies. Proportions of males and the 95% confidence intervals (CIs) are indicated. The vertical dotted lines represent the combined proportion of all studies. The diamond represents the combined 95% CI, the left and right endpoints of which are the lower and upper bounds of the CI, respectively. Critical case defined as: received mechanical ventilation, clinically diagnosed with shock, received care in the intensive care unit (ICU), or transferred to a tertiary care hospital. **(A)** Critical cases in Asian countries. **(C)** Critical Cases in western countries. **(B,D)** Funnel plot with 95% confidence region of sex-distribution in COVID-19 critical cases in each of the studies.](fmed-07-00348-g0006){#F6}

A total of 4 studies from Western regions with a total of 1,787 critical COVID-19 cases were analyzed. Our results from the randomized effects model meta-analysis showed that in the sex-distribution of COVID-19 critically ill cases from the West, males accounted for 70% (95% CI \[0.59, 0.82\]) ([Figure 6C](#F6){ref-type="fig"}). Female patients made up 30% of all COVID-19 critical cases in the West. There was large heterogeneity between the critical population proportions (*I*^2^ = 86%, τ = 0.0103). A funnel plot was drawn to assess the publication bias in studies from the West ([Figure 6D](#F6){ref-type="fig"}). The publication bias test results: Egger\'s test (*p* = 0.04) indicated that there could be some publication bias introduced by the Grasselli et al. ([@B22]) study, as indicated previously. We performed a difference of proportions test among critically ill cases in Asia and the West. There was no statistically significant difference between these two groups (*p* = 0.96). This comparative subgroup analysis of Asia and the West indicated that there was no geography-specific difference in the proportion of critically ill COVID-19 male patients. However, indicated by the moderate to large heterogeneity observed, there are likely variations in male proportion between different studies and regions.

Disease Severity Stratification and Age Distribution
----------------------------------------------------

When extracting male and female proportions for each of the four COVID-19 disease severity categories, we obtained the age distributions of the cases stated as a mean ± SD or median and interquartile range (IQR). Using a skewed distribution assumption, the ages were aggregated as medians with 95% confidence intervals. The median age for all COVID-19 cases was 50, severe cases was 61, critically ill cases was 63, and mortality was 70 ([Figure 7](#F7){ref-type="fig"}). A Kruskal-Wallis ranked-sum test conducted on the medians showed that age was significantly different between the COVID-19 disease severity groups (chi-squared = 24.07, df = 3, *p* = \< 0.0001). Our data confirm that advanced age is a risk factor for more severe clinical outcomes and mortality related to COVID-19.

![The median age of COVID-19 patients stratified according to disease severity. The median age of COVID-19 patients in all cases, severe cases, critically ill cases, and mortalities. Error bars represent 95% confidence intervals of the median. The median age for all COVID-19 cases was 50, severe cases was 61, critically ill cases was 63, and mortality was 70. A Kruskal-Wallis ranked-sum test conducted on the medians showed that age was significantly different amount the COVID-19 disease severity groups (chi-squared = 24.07, df = 3, *p* = \<0.0001).](fmed-07-00348-g0007){#F7}

Discussion {#s4}
==========

In our systematic review and meta-analysis, we set forth to address the question of whether male sex is a risk factor for COVID-19 susceptibility, severe forms of the disease, or mortality related to COVID-19. Systematically reviewing all literature from December 15th, 2019, to April 16th, 2020, we selected 31 research studies that met our selection criteria and performed a meta-analysis on COVID-19 clinical outcomes. Our quality assessment measures indicated small heterogeneity in terms of a single-arm meta-analysis, and the sensitivity analysis showed that there was minimal publication bias. As of the time of completing this manuscript, there were no randomized controlled trials with COVID-19 patients that could address this particular question. The use of non-randomized studies for the meta-analysis is a limitation of this study. However, Abraham et al. ([@B67]) suggested that, in the absence of randomized, controlled trials, that a well-designed meta-analysis using non-randomized controlled trials can also present a high level of evidence ([@B67]).

The four clinical outcome categories (overall, severe, critical, mortality) exhibited different levels of heterogeneity in our random-effects models. The different heterogeneities observed in some outcome categories is a potential limitation of this study. The explanation for these differences is most likely the region of the studies done within each category. The 23 overall studies exhibited 64% heterogeneity with one from Singapore and one from Great Britain. The eight severe studies exhibited 0% heterogeneity, all being from China. The nine critical studies exhibited 83% heterogeneity, with five from China, three from Europe, and one from the United States. The six mortality studies exhibited 35% heterogeneity, with five from China and one from South Korea. The use of a randomized effects model for our meta-analysis takes into account these heterogeneities observed between different studies and regions. Based on the random-effects models shown, there appears to be a difference in the proportions of males with COVID-19 between at least some of the studies or regions. Due to the study designs, their sampling methods, and limited regions included in this study, it is neither possible nor wise to be more specific. This is a potential avenue for further research.

A few systematic review studies looking at COVID-19 risk factors, clinical characteristics and predictive models identified male sex as a risk factor for either disease incidence or mortality ([@B25], [@B51], [@B68]--[@B70]). Our study findings further confirm these observations. In contrast to previous studies, this study is the first systematic analysis that specifically looks at sex-specific clinical outcomes detailing COVID-19 severity (severe, critically ill, and mortality). Our study selection criteria also allowed the inclusion of a wider representation of sex-specific clinical studies and sample populations, as our study focus was only on patient clinical outcomes.

Our meta-analysis showed that while males accounted for 53% of all COVID-19 cases, males accounted for an increasing proportion of severe cases (56%), critically ill cases (71%), and mortalities (69%) compared to their counterpart. While similar male to female disproportions was observed among a few other studies looking at clinical characteristics of COVID-19, our study provides a comprehensive synthesis of data available across different world regions. This study helps establish male sex as a risk factor for COVID-19 clinical outcomes and shows that it is consistent in Asia and Western regions.

This study results do not come as a surprise. Several studies conducted on the two previous coronavirus epidemics, SARS CoV-1in 2002--2003 and MERS in 2012--2013, showed similar patterns with a male predominance toward greater severity and mortality risks. Studies on mortality rates during the MERS-CoV epidemic showed the male sex to be a risk factor ([@B71]--[@B73]). Epidemiological studies with SARS-CoV-1 showed similar patterns ([@B74]). To further support previous epidemiological observations, in controlled mouse model experiments, SARS-CoV-1 has displayed infectious dose-dependent higher mortality rates in male mice compared to female mice ([@B15]). The mounting amount of evidence showing differences among males and female clinical outcomes to coronavirus infections highlights the importance of patient sex in determining the COVID-19 prognosis.

From a clinical standpoint, this information is very pertinent to the practice of patient care. As COVID-19 clinical outcomes are strongly associated with male sex, this can help guide preventative and treatment strategies. Male patients will likely warrant more aggressive inpatient care measures, and especially those that have other COVID-19 risk factors such as advanced age or underlying comorbidities. Susceptible males with other known risk factors may need to take extra precautions to help prevent SARS-CoV-2 infection. Infected males can be encouraged to obtain medical care at an earlier stage of the disease. In cases that require hospitalization, physicians should take into account that medical management could be more difficult in male patients as they are at higher risk of severe disease and mortality.

In addition to preventative and COVID-19 treatment measures, this presents a unique clinical opportunity to address male and female differences at the molecular level, immunological response, and endocrine function ([@B5], [@B11], [@B13], [@B75]). For example, SARS-CoV-2 binds to the Angiotensin-converting enzyme 2 (ACE2) receptors and use it as a mechanism for host cell entry ([@B76]). Males have been shown to express more ACE2 receptors within the renin-angiotensin-aldosterone system (RAAS) ([@B77]). This is likely to play an essential role in the severity of this disease observed in males ([@B77]). Differences in male and female immunological responses will also be a clinically significant factor that can be appropriately modulated to better serve COVID-19 patients ([@B8], [@B12]). Besides sex-specific differences in immunological responses, hormonal regulation and the role of estrogen and testosterone in priming the ACE2 receptor sensitivity could hold the key to better explain the higher COVID-19 severity and mortality rates observed in males ([@B78]--[@B80]). In an age of personalized medicine, if the molecular level of differences in the disease processes of SARS-CoV-2 infection can be characterized with appropriate research, clinicians will be able to use targeted therapy using to promote health equality and help save more lives.
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